Welcome to our new website
As well as being able to load content faster than ever before, you'll now find it's much easier to find all the content you need about the Asian business world.
Health Technology
Dr. Reddy's Laboratories Ltd.
- 2,129.15 INR
- -27.10
- -1.26%
India
Apr 24, 2018Ticker
BOM(500124)Prev. close
2,156.25Market cap (INR)
357,605.37MMarket cap (USD)
5,389.37MShares
165.84M
In the news
- Reliance Industries, Yes Bank power India shares to near three-month highs Apr 24, 2018
- India shares advance for sixth day as software exporters gain Apr 12, 2018
- Indian shares rise on smaller-than-expected government borrowing plan Mar 27, 2018
- India shares rise to three-week highs as automakers advance Feb 26, 2018
- US drug regulator finds violations at Sun Pharma's key plant Feb 23, 2018 See more articles on Dr. Reddy's Laboratories Ltd.
Business Summary
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates from hit generation to pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
Financial Highlights
| Mar 2017 | INR | USD |
| Revenue | 140,809M | 2,099.83M |
| Gross Profit | 73,531M | 1,096.54M |
| Operating income | 12,878M | 192.04M |
| Income before tax | 14,304M | 213.31M |
| Net income | 12,039M | 179.53M |
| EBITDA | 24,155M | 360.21M |
| Diluted EPS | 72.09 | 1.07 |
| Dividends Per Share | 20 | 0.29 |
| Total Assets | 219,821M | 3,385.24M |
| Total liabilities | 95,777M | 1,474.96M |
| Total equity | 124,044M | 1,910.27M |
| Operating cash flow | 21,216M | 316.38M |
| Currency in INR | Currency in USD |
Historical Data
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | |
| Revenue | 116,266M | 132,170M | 148,189M | 154,708M | 140,809M |
| Gross Profit | 58,013M | 72,466M | 81,457M | 87,272M | 73,531M |
| Operating income | 19,489M | 24,119M | 25,878M | 28,806M | 12,878M |
| Income before tax | 21,572M | 26,432M | 27,968M | 26,911M | 14,304M |
| Net income | 16,777M | 21,515M | 22,179M | 20,013M | 12,039M |
| EBITDA | 25,038M | 31,225M | 33,978M | 39,056M | 24,155M |
| Diluted EPS | 98.44 | 126.04 | 129.75 | 116.99 | 72.09 |
| Dividends Per Share | 15 | 18 | 20 | 20 | 20 |
| Total Assets | 142,369M | 170,223M | 194,762M | 207,650M | 219,821M |
| Total liabilities | 69,564M | 79,422M | 83,460M | 79,314M | 95,777M |
| Total equity | 72,785M | 90,801M | 111,302M | 128,336M | 124,044M |
| Operating cash flow | 12,904M | 19,280M | 24,760M | 41,613M | 21,216M |
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | |
| Revenue | 2,136.24M | 2,187.00M | 2,423.62M | 2,363.00M | 2,099.83M |
| Gross Profit | 1,065.91M | 1,199.08M | 1,332.22M | 1,332.99M | 1,096.54M |
| Operating income | 358.08M | 399.09M | 423.23M | 439.98M | 192.04M |
| Income before tax | 396.35M | 437.36M | 457.41M | 411.03M | 213.31M |
| Net income | 308.25M | 356.00M | 362.73M | 305.67M | 179.53M |
| EBITDA | 460.04M | 516.67M | 555.70M | 596.54M | 360.21M |
| Diluted EPS | 1.80 | 2.08 | 2.12 | 1.78 | 1.07 |
| Dividends Per Share | 0.27 | 0.29 | 0.32 | 0.30 | 0.29 |
| Total Assets | 2,619.48M | 2,850.23M | 3,112.14M | 3,135.64M | 3,385.24M |
| Total liabilities | 1,279.92M | 1,329.85M | 1,333.62M | 1,197.68M | 1,474.96M |
| Total equity | 1,339.19M | 1,520.38M | 1,778.51M | 1,937.95M | 1,910.27M |
| Operating cash flow | 237.09M | 319.02M | 404.94M | 635.59M | 316.38M |
Valuation Measures
| Mar 2017 | |
| PER | 36.44 |
| ROA | 5.63% |
| ROE | 9.54% |
| Operating margin | 9.14% |
| Profit margin | 8.54% |
Key executives
- Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
- President, CFO & Global Head-IT: Saumen Chakraborty
- Chief Operating Officer: Erez Israeli
- Secretary & Compliance Officer: Sandeep Poddar
- EVP, Head-Emerging Markets & Global Generics: M. V. Ramana
Shareholders
- Dr. Reddy's Holdings Ltd. (24.7%)
- First State Investment Management (UK) Ltd. (6.2%)
- OppenheimerFunds, Inc. (3.8%)
- Life Insurance Corp. of India (3.5%)
- Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (2.3%)
- BlackRock Fund Advisors (2.1%)
- Franklin Advisers, Inc. (1.9%)
- Franklin Templeton Asset Management (India) Pvt Ltd. (1.8%)
- Aditya Birla Sun Life AMC Ltd. (1.6%)
- TELUK KEMANG INVESTMENTS MAURITIUS LTD (1.2%)
Contact Details
- Website:http://www.drreddys.com
- Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
- Phone: +91.40.49002900
Related Companies
- Dr. Reddy's New Zealand Ltd.
- Imperial Credit Pvt Ltd.
- Ducere Pharma LLC/Otc Bus/
- UCB SA /Established Product Bus/
- Dr. Reddy's Laboratories SA
- Dr. Reddy's Laboratories Ltd. (Russia)
- Zenovus Biotech Pvt Ltd.
- Reddy Holding GmbH
- Dr. Reddy's Pharma SEZ Ltd.
- Dr. Reddy's Bio-Sciences Ltd.
- Promius Pharma LLC
- Industrias Quimicas Falcon de Mexico SA de CV
- DR Reddy's Laboratories (UK) Ltd.
- Kunshan Rotam Reddy Pharmaceutical Co. Ltd.
- Perlecan Pharma Pvt Ltd.
- Macred India Pvt Ltd.
- BASF SE /Pharmaceutical Contract Manufacturing Unit/
- Reddy Pharma Italia SpA
- Dowpharma /Small Molecules Business/
- Dr. Reddy's Laboratories, Inc.
- Laboratorios Litaphar SA
- F. Hoffmann-La Roche Ltd. /Drug Ingredient Making Plant/
- Trigenesis Therapeutics, Inc.
- betapharm Arzneimittel GmbH
- OctoPlus N.V.
- Dr. Reddy's Laboratories (EU) Ltd
- Cheminor Drugs
Competitors
- Novartis AG
- Perrigo Co. Plc
- Lupin Limited
- Mylan N.V.
- Pfizer Inc.
- KRKA dd
- Sanofi
- Pfizer India Ltd.
- Cipla Limited
- Teva Pharmaceutical Industries Limited
- GlaxoSmithKline Pharmaceuticals Limited
- Sanofi India Limited
- Takeda Pharmaceutical Co. Ltd.
- Bayer AG
- Endo International Plc
- Chemical Works of Gedeon Richter Plc
- Alkem Laboratories Ltd.
- STADA Arzneimittel AG
- Cadila Healthcare Limited
- Sun Pharmaceutical Industries Limited
- Abbott India Limited
- Piramal Enterprises Ltd.
- GlaxoSmithkline Consumer Healthcare Ltd
- Fresenius SE & Co. KGaA
- Thermo Fisher Scientific Inc.
- Divi's Laboratories Limited
- Aurobindo Pharma Ltd
- Catalent Inc
- Dishman Carbogen Amcis Ltd.
- Cambrex Corporation
Copyright © 2018 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Apr, 2018You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month
Your full access to the Nikkei Asian Review has expired
